Physician profile
Neil Shinder
NPI 1245258243
$4,396.61
in general payments reported to CMS, 2019-2025
26 companies · $459 in 2025
The $459 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $103 · 2021: $147 · 2022: $794 · 2023: $1,275 · 2024: $1,464 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187 · Education: $10.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.44 |
| Education | $10.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,092.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $612.65 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $485.13 | 2022-2024 | |
| Novo Nordisk INC | $436.90 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $289.34 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $259.34 | 2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.67 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $211.60 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $186.09 | 2024-2025 | Dupixent |
| Amgen INC. | $178.87 | 2023-2024 | Tezspire, Otezla, Repatha |
| Mylan Specialty L.P. | $61.38 | 2022-2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $46.42 | 2024-2025 | Livalo, Zoryve |
| Philips North America LLC | $36.25 | 2021 | |
| Lilly USA, LLC | $35.92 | 2022-2025 | Zepbound, Mounjaro |
| Covis Pharma Gmbh | $27.83 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $24.27 | 2022 | |
| Resmed Corp | $23.75 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $22.56 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $22.12 | 2023 | Quviviq |
| Abbvie INC. | $21.00 | 2025 | |
| Grifols USA, LLC | $20.49 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.03 | 2023 | Glassia |
| Merck Sharp & Dohme LLC | $17.41 | 2023 | Belsomra |
| Sumitomo Pharma America, INC. | $14.63 | 2023 | Gemtesa |
| 3b Medical, INC. | $13.33 | 2023 | Luna |
| Inspire Medical Systems, INC. | $13.11 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Shinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.